Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
US8580926B2 · kind B2 · utility
0Cited by
18References
13Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 18, 2009 |
| Grant date | Nov 12, 2013 |
| Priority date | — |
| Expiry date | May 17, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.